Testing repeat doses of a stem cell and virus treatment for glioblastoma that has come back
Original title: Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test of safety in a small group of people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests if giving several doses of a new treatment into the brain is safe.
Who this trial is for. This trial is for people whose glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary has come back for the first time. It tests the safety of giving several doses of a treatment right into the brain.
Where it stands. This is a first test in people. The main question is whether several doses are safe. The trial has not reported results yet.
What this means, and what it doesn't
What it could mean: The treatment uses special cells that can find tumor cells. These cells carry a virus that can kill cancer cells. The idea is that more doses may kill more tumor cells. If your glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary has come back for the first time, you could ask your care team about this trial.
What it doesn't mean: This trial is a test. It is not a proven treatment. Being in it does not mean it will help you. It is not a cure. The trial team decides who can join.
Source: ClinicalTrials.gov, September 9, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.